RESUMO
La efectividad de la terapia con fármacos antifactor de necrosis tumoral alpha en la enfermedad inflamatoria intestinal ha sido probada en la práctica clínica. Tras más de una década de uso de este tipo de fármacos, surge la interrogante acerca de si existe un momento apropiado para suspender estas terapias, y de qué manera esta debiera realizarse. Esta revisión tiene por objetivo evaluar la evidencia actual acerca del retiro de la terapia con antifactor de necrosis tumoral alpha y, eventualmente, identificar las condiciones o los subgrupos de pacientes potencialmente candidatos a la suspensión o el retiro de esta
Anti-tumour necrosis factor alpha therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor alpha therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal
Assuntos
Humanos , Doenças Inflamatórias Intestinais/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Suspensão de TratamentoRESUMO
Anti-tumour necrosis factor α therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these therapies, and how this should be done. This review aims to evaluate the current evidence on these topics concerning anti-tumour necrosis factor α therapies, and eventually identify conditions and subgroups of patients that could potentially be candidates for withdrawal.
